152 related articles for article (PubMed ID: 11117535)
1. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling.
Zhou Y; Sun H; Danila DC; Johnson SR; Sigai DP; Zhang X; Klibanski A
Mol Endocrinol; 2000 Dec; 14(12):2066-75. PubMed ID: 11117535
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.
Danila DC; Zhang X; Zhou Y; Haidar JN; Klibanski A
J Clin Endocrinol Metab; 2002 Oct; 87(10):4741-6. PubMed ID: 12364468
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
Alexander JM; Bikkal HA; Zervas NT; Laws ER; Klibanski A
J Clin Endocrinol Metab; 1996 Feb; 81(2):783-90. PubMed ID: 8636304
[TBL] [Abstract][Full Text] [Related]
4. Truncated activin type II receptor inhibits erythroid differentiation in K562 cells.
Liu F; Shao LE; Yu J
J Cell Biochem; 2000 Apr; 78(1):24-33. PubMed ID: 10797563
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors.
D'Abronzo FH; Swearingen B; Klibanski A; Alexander JM
J Clin Endocrinol Metab; 1999 May; 84(5):1716-21. PubMed ID: 10323406
[TBL] [Abstract][Full Text] [Related]
6. Activin effects on neoplastic proliferation of human pituitary tumors.
Danila DC; Inder WJ; Zhang X; Alexander JM; Swearingen B; Hedley-Whyte ET; Klibanski A
J Clin Endocrinol Metab; 2000 Mar; 85(3):1009-15. PubMed ID: 10720031
[TBL] [Abstract][Full Text] [Related]
7. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells.
Piek E; Afrakhte M; Sampath K; van Zoelen EJ; Heldin CH; ten Dijke P
J Cell Physiol; 1999 Aug; 180(2):141-9. PubMed ID: 10395283
[TBL] [Abstract][Full Text] [Related]
8. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells.
Bernard DJ; Lee KB; Santos MM
Reprod Biol Endocrinol; 2006 Oct; 4():52. PubMed ID: 17040568
[TBL] [Abstract][Full Text] [Related]
9. Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors.
De Winter JP; De Vries CJ; Van Achterberg TA; Ameerun RF; Feijen A; Sugino H; De Waele P; Huylebroeck D; Verschueren K; Van Den Eijden-Van Raaij AJ
Exp Cell Res; 1996 May; 224(2):323-34. PubMed ID: 8612709
[TBL] [Abstract][Full Text] [Related]
10. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
Lewis KA; Gray PC; Blount AL; MacConell LA; Wiater E; Bilezikjian LM; Vale W
Nature; 2000 Mar; 404(6776):411-4. PubMed ID: 10746731
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3.
Takumi T; Moustakas A; Lin HY; Lodish HF
Exp Cell Res; 1995 Jan; 216(1):208-14. PubMed ID: 7813622
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of activin-dependent transcription by kinase-deficient activin receptors.
Tsuchida K; Vaughan JM; Wiater E; Gaddy-Kurten D; Vale WW
Endocrinology; 1995 Dec; 136(12):5493-503. PubMed ID: 7588300
[TBL] [Abstract][Full Text] [Related]
13. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
14. Activin A and activin receptors in the human thyroid: a link to the female predominance of goiter?
Schulte KM; Jonas C; Krebs R; Röher HD
Horm Metab Res; 2000 Oct; 32(10):390-400. PubMed ID: 11069203
[TBL] [Abstract][Full Text] [Related]
15. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells.
Bilezikjian LM; Corrigan AZ; Blount AL; Chen Y; Vale WW
Endocrinology; 2001 Mar; 142(3):1065-72. PubMed ID: 11181520
[TBL] [Abstract][Full Text] [Related]
16. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.
Lebrun JJ; Vale WW
Mol Cell Biol; 1997 Mar; 17(3):1682-91. PubMed ID: 9032295
[TBL] [Abstract][Full Text] [Related]
17. A human pituitary tumor-derived folliculostellate cell line.
Danila DC; Zhang X; Zhou Y; Dickersin GR; Fletcher JA; Hedley-Whyte ET; Selig MK; Johnson SR; Klibanski A
J Clin Endocrinol Metab; 2000 Mar; 85(3):1180-7. PubMed ID: 10720059
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
Kaivo-Oja N; Mottershead DG; Mazerbourg S; Myllymaa S; Duprat S; Gilchrist RB; Groome NP; Hsueh AJ; Ritvos O
J Clin Endocrinol Metab; 2005 Jan; 90(1):271-8. PubMed ID: 15483083
[TBL] [Abstract][Full Text] [Related]
19. Identification of a functional binding site for activin on the type I receptor ALK4.
Harrison CA; Gray PC; Koerber SC; Fischer W; Vale W
J Biol Chem; 2003 Jun; 278(23):21129-35. PubMed ID: 12665502
[TBL] [Abstract][Full Text] [Related]
20. Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter.
Ezzat S; Yu S; Asa SL
Am J Pathol; 2003 Sep; 163(3):1177-84. PubMed ID: 12937159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
